Drug Shortage Report for MAGNESIUM SULFATE INJECTION, USP
Report ID | 127839 |
Drug Identification Number | 02139499 |
Brand name | MAGNESIUM SULFATE INJECTION |
Common or Proper name | Magnesium Sulfate Injection |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | MAGNESIUM SULFATE |
Strength(s) | 500MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS |
Packaging size | 500 mg/mL, SD Vial, 50 mL |
ATC code | B05XA |
ATC description | I.V. SOLUTION ADDITIVES |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2020-11-04 |
Estimated end date | Unknown |
Actual end date | 2020-12-22 |
Shortage status | Resolved |
Updated date | 2021-01-26 |
Company comments | Fresenius Kabi Canada Ltd. regrets to advise that due to increased demand and production delays, we will be placing this product on 50% allocation effective today, Wednesday, November 4, 2020. AND C96410P to cover 50 % of the 50 mL demand on a 5:1 ratio) UPDATE Fresenius Kabi Canada Ltd. is pleased to advise that we will be increasing the allocation placed on our Magnesium Sulfate Injection 500 mg/mL SD Vial 50 mL to 100% effective December 22, 2020. Please note that Magnesium Sulfate Injection 500 mg/mL SD Vial 10 mL remains on 100% allocation. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2021-01-26 | French | Compare |
v3 | 2021-01-26 | English | Compare |
v2 | 2020-11-05 | French | Compare |
v1 | 2020-11-05 | English | Compare |
Showing 1 to 4 of 4